Cold Agglutinin Disease Clinical Trial
Official title:
An Open-label Study for Sutimlimab in Participants With Cold Agglutinin Disease (CAD) Who Have Completed the CARDINAL Study (BIVV009-03/EFC16215, Part B) or CADENZA Study (BIVV009-04/EFC16216, Part B) in Japan
This was a multi-center, single treatment-group, open-label study to provide sutimlimab to the adult participants with cold agglutinin disease (CAD) who had completed the CARDINAL (NCT number: NCT03347396) or CADENZA (NCT number: NCT03347422) studies and benefitted from sutimlimab treatment in Japan. • Study and treatment duration: the period between the participant's completion of the CARDINAL and CADENZA studies and sutimlimab or other appropriate CAD therapy becoming commercially available to participants in Japan.
The period between screening/baseline visit (upon the participant's completion* of the CARDINAL and CADENZA studies) and end of treatment with sutimlimab in this study was determined by sutimlimab or other appropriate CAD therapy becoming commercially available to participants in Japan. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT05096403 -
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
|
Phase 3 | |
| Completed |
NCT03347422 -
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion
|
Phase 3 | |
| Completed |
NCT00960713 -
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
|
N/A | |
| Completed |
NCT00373594 -
Therapy for Chronic Cold Agglutinin Disease
|
Phase 2 | |
| Recruiting |
NCT05931718 -
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
|
||
| Recruiting |
NCT05757570 -
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias
|
Phase 1/Phase 2 | |
| Completed |
NCT02689986 -
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
|
Phase 2 | |
| Completed |
NCT01303952 -
Therapy of Chronic Cold Agglutinin Disease With Eculizumab
|
Phase 2 | |
| Completed |
NCT03226678 -
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
|
Phase 2 |